Loss of CDX2 gene expression is associated with DNA repair proteins and is a crucial member of the Wnt signaling pathway in liver metastasis of colorectal cancer

Tóth,Csaba; Sükösd,Farkas; Valicsek,Erzsébet; Herpel,Esther; Schirmacher,Peter; Tiszlavicz,László

doi:10.3892/ol.2018.7756

Loss of CDX2 gene expression is associated with DNA repair proteins and is a crucial member of the Wnt signaling pathway in liver metastasis of colorectal cancer

Authors:
- Csaba Tóth
- Farkas Sükösd
- Erzsébet Valicsek
- Esther Herpel
- Peter Schirmacher
- László Tiszlavicz
View Affiliations

Affiliations: Institute of Pathology, University Hospital Heidelberg, D‑69120 Heidelberg, Germany, Department of Pathology, University of Szeged, 6725 Szeged, Hungary, Department of Oncotherapy, University of Szeged, 6725 Szeged, Hungary
Published online on: January 9, 2018 https://doi.org/10.3892/ol.2018.7756
Pages: 3586-3593
Copyright: © Tóth et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Caudal type homeobox 2 (CDX2) has been well‑established as a diagnostic marker for colorectal cancer (CRC); however, less is known about its regulation, particularly its potential interactions with the DNA repair proteins, adenomatous polyposis coli (APC) and β‑catenin, in a non‑transcriptional manner. In the present study, the protein expression of CDX2 was analyzed, depending on the expression of the DNA repair proteins, mismatch repair (MMR), O6‑methylguanine DNA methyltransferase (MGMT) and excision repair cross‑complementing 1 (ERCC1), and its importance in Wnt signaling was also determined. A total of 101 liver metastases were punched into tissue microarray (TMA) blocks and serial sections were cut for immunohistochemistry. For each protein, an immunoreactive score was generated according to literature data and the scores were fitted to TMA. Subsequently, statistical analysis was performed to compare the levels of expression with each other and with clinical data. CDX2 loss of expression was observed in 38.5% of the CRC liver metastasis cases. A statistically significant association between CDX2 and each of the investigated MMRs was observed: MutL Homolog 1 (P<0.01), MutS protein Homolog (MSH) 2 (P<0.01), MSH6 (P<0.01), and postmeiotic segregation increased 2 (P=0.040). Furthermore, loss of MGMT and ERCC1 was also associated with CDX2 loss (P=0.039 and P<0.01, respectively). In addition, CDX2 and ERCC1 were inversely associated with metastatic tumor size (P=0.038 and P=0.027, respectively). Sustained CDX2 expression was associated with a higher expression of cytoplasmic/membranous β‑catenin and with nuclear APC expression (P=0.042 and P<0.01, respectively). In conclusion, CDX2 loss of expression was not a rare event in liver metastasis of CRC and the results suggested that CDX2 may be involved in mechanisms resulting in the loss of DNA repair protein expression, and in turn methylation; however, its exact function in this context remains to be elucidated.

View Figures

View References

1	Hryniuk A, Grainger S, Savory JG and Lohnes D: Cdx1 and Cdx2 function as tumor suppressors. J Biol Chem. 289:33343–33354. 2014. View Article : Google Scholar : PubMed/NCBI
2	Misiakos EP, Karidis NP and Kouraklis G: Current treatment for colorectal liver metastases. World J Gastroenterol. 17:4067–4075. 2011. View Article : Google Scholar : PubMed/NCBI
3	Olsen J, Espersen ML, Jess P, Kirkeby LT and Troelsen JT: The clinical perspectives of CDX2 expression in colorectal cancer: A qualitative systematic review. Surg Oncol. 23:167–176. 2014. View Article : Google Scholar : PubMed/NCBI
4	Olsen AK, Coskun M, Bzorek M, Kristensen MH, Danielsen ET, Jørgensen S, Olsen J, Engel U, Holck S and Troelsen JT: Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells. Carcinogenesis. 34:1361–1369. 2013. View Article : Google Scholar : PubMed/NCBI
5	Zlobec I, Bihl M, Foerster A, Rufle A and Lugli A: Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol. 225:336–343. 2011. View Article : Google Scholar : PubMed/NCBI
6	Renouf B, Soret C, Saandi T, Delalande F, Martin E, Vanier M, Duluc I, Gross I, Freund JN and Domon-Dell C: Cdx2 homeoprotein inhibits non-homologous end joining in colon cancer but not in leukemia cells. Nucleic Acids Res. 40:3456–3469. 2012. View Article : Google Scholar : PubMed/NCBI
7	Li X, Hu F, Wang Y, Yao X, Zhang Z, Wang F, Sun G, Cui BB, Dong X and Zhao Y: CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China. Biomed Res Int. 2014:2363612014. View Article : Google Scholar : PubMed/NCBI
8	Inno A, Fanetti G, Di Bartolomeo M, Gori S, Maggi C, Cirillo M, Iacovelli R, Nichetti F, Martinetti A and de Braud F: Role of MGMT as biomarker in colorectal cancer. World J Clin Cases. 2:835–839. 2014. View Article : Google Scholar : PubMed/NCBI
9	Hassen S, Ali N and Chowdhury P: Molecular signaling mechanisms of apoptosis in hereditary non-polyposis colorectal cancer. World J Gastrointest Pathophysiol. 3:71–79. 2012. View Article : Google Scholar : PubMed/NCBI
10	Sayar I, Akbas EM, Isik A, Gokce A, Peker K, Demirtas L and Gürbüzel M: Relationship among mismatch repair deficiency, CDX2 loss, p53 and E-cadherin in colon carcinoma and suitability of using a double panel of mismatch repair proteins by immunohistochemistry. Pol J Pathol. 66:246–253. 2015. View Article : Google Scholar : PubMed/NCBI
11	Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y and Wang D: Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother Pharmacol. 74:777–786. 2014. View Article : Google Scholar : PubMed/NCBI
12	Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, et al: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 25:1247–1254. 2007. View Article : Google Scholar : PubMed/NCBI
13	Persad S, Troussard AA, McPhee TR, Mulholland DJ and Dedhar S: Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol. 153:1161–1174. 2001. View Article : Google Scholar : PubMed/NCBI
14	Henderson BR and Fagotto F: The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep. 3:834–839. 2002. View Article : Google Scholar : PubMed/NCBI
15	Polakis P: Wnt signaling and cancer. Genes Dev. 14:1837–1851. 2000.PubMed/NCBI
16	Camp RL, Charette LA and Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest. 80:1943–1949. 2000. View Article : Google Scholar : PubMed/NCBI
17	Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, et al: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 159:2249–2256. 2001. View Article : Google Scholar : PubMed/NCBI
18	Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, et al: Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
19	Toth C, Meinrath J, Herpel E, Derix J, Fries J, Buettner R, Schirmacher P and Heikaus S: Expression of the apoptosis repressor with caspase recruitment domain (ARC) in liver metastasis of colorectal cancer and its correlation with DNA mismatch repair proteins and p53. J Cancer Res Clin Oncol. 142:927–935. 2015. View Article : Google Scholar : PubMed/NCBI
20	Gerhard R, Carvalho A, Carneiro V, Bento RS, Uemura G, Gomes M, Albergaria A and Schmitt F: Clinicopathological significance of ERCC1 expression in breast cancer. Pathol Res Pract. 209:331–336. 2013. View Article : Google Scholar : PubMed/NCBI
21	Dawson H, Galvan JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, Economou M, Hammer C, Lugli A and Zlobec I: Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer. 134:2342–2351. 2014. View Article : Google Scholar : PubMed/NCBI
22	Dawson H, Koelzer VH, Lukesch AC, Mallaev M, Inderbitzin D, Lugli A and Zlobec I: Loss of Cdx2 expression in primary tumors and lymph node metastases is specific for mismatch repair-deficiency in colorectal cancer. Front Oncol. 3:2652013. View Article : Google Scholar : PubMed/NCBI
23	Halford S, Rowan A, Sawyer E, Talbot I and Tomlinson I: O(6)-methylguanine methyltransferase in colorectal cancers: Detection of mutations, loss of expression and weak association with G:C>A:T transitions. Gut. 54:797–802. 2005. View Article : Google Scholar : PubMed/NCBI
24	Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, Satoh Y, Matsukura S, Kudo S, Kitajima Y, Harada H, et al: Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene. 22:8835–8844. 2003. View Article : Google Scholar : PubMed/NCBI
25	Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC and Gambari R: Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). Int J Oncol. 47:417–428. 2015. View Article : Google Scholar : PubMed/NCBI
26	Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
27	Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH, Wesseling P, Hulsebos TJ, Troost D, van Tilborg AA, et al: The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol. 16:1263–1273. 2014. View Article : Google Scholar : PubMed/NCBI
28	Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, et al: MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 97:1330–1338. 2005. View Article : Google Scholar : PubMed/NCBI
29	Kalogeraki A, Karvela-Kalogeraki I, Tamiolakis D, Petraki P, Saridaki Z and Tzardi M: ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples. Rev Port Pneumol. 20:200–207. 2014. View Article : Google Scholar : PubMed/NCBI
30	Facista A, Nguyen H, Lewis C, Prasad AR, Ramsey L, Zaitlin B, Nfonsam V, Krouse RS, Bernstein H, Payne CM, et al: Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer. Genome Integr. 3:32012. View Article : Google Scholar : PubMed/NCBI
31	Smith DH, Fiehn AM, Fogh L, Christensen IJ, Hansen TP, Stenvang J, Nielsen HJ, Nielsen KV, Hasselby JP, Brünner N and Jensen SS: Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody. Sci Rep. 4:43132014. View Article : Google Scholar : PubMed/NCBI
32	Chen HY, Shao CJ, Chen FR, Kwan AL and Chen ZP: Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer. 126:1944–1954. 2010.PubMed/NCBI
33	Borrmann L, Schwanbeck R, Heyduk T, Seebeck B, Rogalla P, Bullerdiek J and Wisniewski JR: High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity. Nucleic Acids Res. 31:6841–6851. 2003. View Article : Google Scholar : PubMed/NCBI
34	Garofalo M and Croce CM: MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat. 16:47–59. 2013. View Article : Google Scholar : PubMed/NCBI
35	Hawkins NJ, Lee JH, Wong JJ, Kwok CT, Ward RL and Hitchins MP: MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol. 22:1588–1599. 2009. View Article : Google Scholar : PubMed/NCBI
36	Kang KJ, Min BH, Ryu KJ, Kim KM, Chang DK, Kim JJ, Rhee JC and Kim YH: The role of the CpG island methylator phenotype on survival outcome in colon cancer. Gut Liver. 9:202–207. 2015. View Article : Google Scholar : PubMed/NCBI
37	Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK and Giles FJ: Wnt/beta-catenin pathway: Modulating anticancer immune response. J Hematol Oncol. 10:1012017. View Article : Google Scholar : PubMed/NCBI
38	Wang L, Liu X, Gusev E, Wang C and Fagotto F: Regulation of the phosphorylation and nuclear import and export of β-catenin by APC and its cancer-related truncated form. J Cell Sci. 127:1647–1659. 2014. View Article : Google Scholar : PubMed/NCBI
39	Efstathiou JA, Noda M, Rowan A, Dixon C, Chinery R, Jawhari A, Hattori T, Wright NA, Bodmer WF and Pignatelli M: Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci USA. 95:pp. 3122–3127. 1998; View Article : Google Scholar : PubMed/NCBI
40	Neufeld KL: Nuclear APC. Adv Exp Med Biol. 656:13–29. 2009. View Article : Google Scholar : PubMed/NCBI
41	Fagman H, Larsson F, Arvidsson Y, Meuller J, Nordling M, Martinsson T, Helmbrecht K, Brabant G and Nilsson M: Nuclear accumulation of full-length and truncated adenomatous polyposis coli protein in tumor cells depends on proliferation. Oncogene. 22:6013–6022. 2003. View Article : Google Scholar : PubMed/NCBI
42	Fodde R, Smits R and Clevers H: APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 1:55–67. 2001. View Article : Google Scholar : PubMed/NCBI